[1]任宝中,李 媛△.益气化瘀方配合化疗治疗晚期非小细胞肺癌临床研究*[J].陕西中医,2019,(8):1036-1040.
　REN Baozhong,LI Yuan..Application effect of TP chemotherapy Plus Yiqi Huayu decoction in advanced Non-small cell lung cancer patients[J].,2019,(8):1036-1040.
点击复制

益气化瘀方配合化疗治疗晚期非小细胞肺癌临床研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年8期
页码:
1036-1040
栏目:
临床研究
出版日期:
2019-08-05

文章信息/Info

Title:
Application effect of TP chemotherapy Plus Yiqi Huayu decoction in advanced Non-small cell lung cancer patients
文章编号:
DOI:10.3969/j.issn.1000-7369.2019.08.014
作者:
任宝中; 李 媛△
陕西省宝鸡市中医医院呼吸内科（ 宝鸡 721001）
Author(s):
REN Baozhong; LI Yuan.
Department of Respiratory Medicine,Baoji Hospital of Traditional Chinese Medicine（Baoji 721001)
关键词:
非小细胞肺癌; 益气化瘀方; 化疗; 生活质量; 自评-主观全面评定量评分; 细胞免疫功能指标评分
Keywords:
Key words NSCLC; Yiqi Huayu decoction; Chemotherapy; quality of life; PG-SGA scale; Cell immune function index score
分类号:
R734.2
文献标志码:
A
摘要:
摘 要 目的：评价益气化瘀方配合TP方案化疗干预在晚期非小细胞肺癌（NSCLC）患者中的应用效果，并探讨机制。方法： 将170例NSCLC患者随机分为两组。对照组85例（最终完成76例）予TP方案化疗；治疗组85例（最终完成79例）在对照组治疗基础上予益气化瘀方治疗。两组均21 d为1个周期，连续治疗4个周期。比较两组自评-主观全面评定量（PG-SGA）评分、生活质量、细胞免疫功能指标评分及不良反应，并统计疗效。结果：两组治疗后PG-SGA评分均低于本组治疗前（P＜0.05），且治疗组低于对照组（P＜0.05）。治疗后治疗组在躯体功能、情绪功能、认知功能、社会功能、角色功能方面评分高于对照组（P＜0.05）。两组治疗后CD3、CD4均较本组治疗前升高（P＜0.05），CD8降低（P＞0.05）；治疗后治疗组CD3、CD4高于对照组（P＜0.05），两组治疗后CD8比较差异无统计学意义（P＞0.05）。治疗组不良反应发生率18.99%(15/79)，对照组不良反应发生率39.47%(30/76)，治疗组不良反应发生率低于对照组（P＜0.05）。治疗组总有效率89.9%（71/79），对照组为73.7%（56/76），两组有效率比较差异有统计学意义（P＜0.05）。结论：在化疗基础上给予益气化瘀方可减轻老年晚期NSCLC患者的临床症状、改善患者生活质量、降低化疗药物不良反应，同时为临床应用PG-SGA量对肺部肿瘤患者营养评估提供理论依据。
Abstract:
Abstract Objective：Evaluate the Yiqi Huayu decoction in advanced Non-small cell lung cancer(NSCLC) patients by patient-generated subjective assessment and explore the mechanism. Methods：Select 170 cases patients that accord with the inclusion criteria then randomly divided into the treatment group (n=85)and control group (n=85);there were 15 cases lost in the study,the lost rate was 8.82%,a total of 155 patients were completed,including 79 in the treatment group and 76 in the control group. The control group was given TP(Paclitaxel+cisplatin) chemotherapy；the treatment group was given Yiqi Huayu decoction on the basis of the control group.Both groups were treated with 21 days as a cycle for 4 consecutive cycles. Then scores of PG-SGA scale,quality of life,cell immune function index score,adverse reaction and efficiency of both group cases were observed and compared. Results：After treatment,PG-SGA scores in both groups were lower than before treatment (P＜0.05)；and the treatment group was lower than the control group (P＜0.05). After treatment,the score of physical function,emotional function,cognitive function,social function and role functions was higher than that of the control group (P＜0.05).The scores of fatigue,nausea,vomiting,pain,loss of appetite,constipation and economic difficulties were all lower than the control group (P＜0.05)；both CD3 and CD4 scores were higher than those before treatment (P＜0.05),and the CD8 score was lower than before treatment (P＞0.05). The treatment group CD3 score and,the CD4 score was higher than control group after the treatment (P＜0.05)；the incidence of adverse reactions of the treatment group was 18.99% (15/79),the incidence of adverse reactions of the control group was 39.47% (30/76)；there were statistically significant differences in the incidence of adverse reactions in the two groups (P＜0.05). The total effective rate of the treatment group was 89.9% (71/79),and the control group was73.7% (56/76).The difference of the two groups 〖LM〗was statistically significant (P＜0.05). Conclusions：Give organic combination therapy of traditional Chinese medicine on the basis of chemotherapy can reduce clinical symptoms of the elderly patients with advanced NSCLC,improve quality of life,reduce the drug adverse reaction of chemotherapy,meanwhile,the PG-SGA scale was used to provide theoretical basis for the nutritional assessment of lung cancer patient.

参考文献/References:

[1] 李 艳,郭其森.晚期非小细胞肺癌维持治疗进展[J].中华肿瘤防治杂志,2014,21(10):800-804.
[2] 刘苓霜,刘嘉湘,沈丽萍,等.中医辨证治疗对晚期非小细胞肺癌巩固治疗的影响[J].中医杂志,2015,56(17):1473-1478.
[3] Counago F,Rodriguez A,Calvo P,et al.Targeted therapy combined with radiotherapy in non-small-cell lung cancer：a review of the oncologic group for the study of lung cancer (spanish radiation oncology society)[J].Clin Transl Oncol,2017,19(1):31-43.
[4] 汪丛丛,刘洪星,庄 静,等.中医药联合同步放化疗治疗晚期非小细胞肺癌疗效及安全性的Meta分析[J].中国全科医学,2015,18(12):1406-1414.
[5] Ottery FD. Rethinking nutritional support of the cancer patient：the new field of nutritional oncology[J].Semin Oncol,1994,21(6):770-778．
[6] Bauer J,Capra S,Ferguson M.Use of the scored patient-generated subjective global assessment (PG-SGA) as a nutrition assessment tool in patients with cancer[J].Eur J Clin Nutr,2002,56(8):779-785．
[7] 支修益,陈东红.肺癌新TNM分期系统解析[J].中国医刊,2010,45(12):87-89．
[8] 支修益,石远凯,于金明,等.中国原发性肺癌诊疗规范：2015年版[J].中华肿瘤杂志,2015,37(1):67-78.
[9] 国家食品药品监督管理总局.中药新药临床研究指导原则（试行）[M].北京:中国中医药科技出版社,2002：216-224.
[10] 万崇华.生命质量测定与评价方法[M].昆明:云南大学出版社,1999:225．
[11] 张俊茹. 癌症患者生活质量评价方法的构建[D].西安：第四军医大学,2012.
[12] 孙 燕,石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2007:147-156．
[13] 李 康,李秋华.中药联合化疗改善晚期非小细胞肺癌患者生活质量临床观察[J].辽宁中医杂志,2016,43(3):523-526.
[14] 苏春雨. 基于大气下陷理论治疗非小细胞肺癌术后相关症状的研究[D]. 北京：北京中医药大学,2016.
[15] Liu TC,Hsieh MJ,Wu WJ,et al.Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer[J].Int J Med Sci,2016,13(12):929-935.
[16] 单孟俊,张丽媛,游 捷.中医辨证疗法联合化疗治疗老年晚期非小细胞肺癌患者随机对照研究[J].中国中西医结合杂志,2018,38(2):163-167.
[17] 宋振民,李 慧,强亚杰,等. 沙参麦冬汤加减联合ＧＰ化疗治疗晚期非小细胞肺癌疗效研究[J]. 陕西中医,2018,39(4):461-463.
[18] 戴韵峰,郭震浪,程 晶,等. 中医辨证论治联合化疗治疗晚期非小细胞肺癌的Meta分析[J]. 中国实验方剂学杂志,2016,22(2):180-185.
[19] 纪云飞,王瑞君,李晓波.复方四君子汤的化学成分和药理作用研究进展[J].中草药,2016,47(5):837-843.
[20] 李 新,刘茂军.沙参麦冬汤加减联合化疗治疗中晚期非小细胞肺癌[J].中国实验方剂学杂志,2014,20(20):195-198.
[21] 杨忠光,梁 鑫,赵远桥.沙参麦冬汤联合化疗对气阴两虚型肺癌患者免疫功能及炎性反应的影响[J].中国实验方剂学杂志,2017,23(16):158-163.
[22] Gupta D,Vashi PG,Lammersfeld CA,et al.Role of nutrition status in predicting the length of stay in cancer:A systematic review of the epidemiological literature[J].Ann Nutr Metab,2011,59(2-4):96-106．
[23] 冯谢敏,赵 红,崔 洁,等. 同步放化疗治疗局部晚期非小细胞肺癌疗效观察[J]. 陕西医学杂志,2018,45(9):1126-1128.
[24] 李 静,毛志音,李怡霖.患者自评-主观全面评定量表及营养干预在胃肠道肿瘤患者中的应用效果[J].中国全科医学,2017,20(S2):144-146.
[25] 于礼建,徐立群,邬晓东,等.参慈胶囊对GP方案治疗晚期非小细胞肺癌的免疫功能及血液学毒性的影响[J].实用医学杂志,2017,33(21):3655-3660.

相似文献/References:

[1]刘月芬,刘小红,于明军,等.清金化痰汤治疗非小细胞肺癌临床研究[J].陕西中医,2019,(2):229.
　LIU Yuefen,LIU Xiaohong,YU Mingjun,et al.Clinical observation of nonsmall cell lung cancer patients treated with Qingjin Huatan decoction[J].,2019,(8):229.
[2]陈姣红,古红莉,员建中,等.参术扶正抗癌汤联合化疗及三维适形放疗对晚期非小细胞肺癌患者 血清T细胞亚群水平及生存质量的影响*[J].陕西中医,2019,(5):564.
[3]张栓宝,严宁娟△,张燕平.复方斑蝥胶囊对非小细胞肺癌患者围术期血清炎症因子及免疫功能的影响[J].陕西中医,2019,(7):890.
[4]任东峰,孙国芳△.六君祛痰解毒汤联合化疗治疗非小细胞肺癌疗效〖JZ〗及对患者血管内皮生长因子的影响[J].陕西中医,2020,(1):63.
[5]刘 婷,李 洋,石志红.灯盏花素对非小细胞肺癌A549细胞的作用及机制研究[J].陕西中医,2021,(10):1363.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.009]
　LIU Ting,LI Yang,SHI Zhihong.Effects of breviscapine on proliferation and apoptosis of non-small cell lung cancer A549 cells[J].,2021,(8):1363.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.009]
[6]肖 凌,王 洋,钱建新,等.生脉饮合沙参麦冬汤联合西药治疗晚期非小细胞肺癌疗效研究[J].陕西中医,2021,(12):1696.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.010]
[7]陈香梅,刘太锋,杨 明,等.复方苦参注射液联合化疗治疗非小细胞肺癌疗效研究[J].陕西中医,2021,(12):1700.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.011]
[8]王理槐,孙银辉,张领兄,等.基于Wnt/β-catenin信号通路探讨血府逐瘀汤在非小细胞肺癌EGFR-TKI获得性耐药中的作用[J].陕西中医,2022,(4):427.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.004]
　WANG Lihuai,SUN Yinhui,ZHANG Lingxiong,et al.Efficacy of Xuefu Zhuyu decoction in EGFR-TKI-Acquired resistance of non-small cell lung carcinoma based on the Wnt/β-catenin signaling pathway[J].,2022,(8):427.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.004]
[9]屈 直,王 芬,李志明,等.二陈汤对Lewis肺癌移植瘤生长及Hedgehog通路蛋白表达的影响[J].陕西中医,2022,(5):555.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.003]
　QU Zhi,WANG Fen,LI Zhiming,et al.Effect of Erchen decoction on the expression of Hedgehog pathway protein in Lewis lung cancer transplanted tumor[J].,2022,(8):555.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.003]
[10]王军徽,肖 萌,马功贤,等.非小细胞肺癌中医药治疗研究进展[J].陕西中医,2023,(11):1663.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.042]
　WANG Junhui,XIAO Meng,MA Gongxian,et al.Research progress in traditional Chinese medicine treatment of non-small cell lung cancer[J].,2023,(8):1663.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.042]

备注/Memo

备注/Memo:
*陕西省中医药管理局科研项目(2017-LCMS034)
更新日期/Last Update: 2019-08-15